Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α

Cancer Letters

Volumn 305, Issue 1, 2011, Pages 94-99

  Su, Wenjing ^a   Huang, Lei ^b   Ao, Qilin ^a   Zhang, Qinghua ^b   Tian, Xun ^b   Fang, Yong ^a   Lu, Yunping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Chemoresistance; Cisplatin; HIF 1 ; Noscapine; Ovarian neoplasm

Indexed keywords

CISPLATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NOSCAPINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SEPARATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NOSCAPINE; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79953201844     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.031     Document Type: Article

References (29)

1. Semenza G.L. Involvement of hypoxia-inducible factor 1 in human cancer. Nat. Rev. Cancer 2003, 3:721-732.
2. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.
3. Huang L., Ao Q., Zhang Q., Yang X., Xing H., Li F., Chen G., Zhou J., Wang S., Xu G., Meng L., Lu Y., Ma D. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J. Cancer Res. Clin. Oncol. 2010, 136:447-456.
4. Chen J., Kobayashi M., Darmanin S., Qiao Y., Gully C., Zhao R., Yeung S.C., Lee M.H. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 2009, 28:2581-2592.
5. Lau C.K., Yang Z.F., Ho D.W., Ng M.N., Yeoh G.C., Poon R.T., Fan S.T. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin. Cancer Res. 2009, 15:3462-3471.
6. Nardinocchi L., Puca R., Sacchi A., D'Orazi G. Inhibition of HIF-1 alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol. Cancer 2009, 8:1.
7. Zhang N., Zhang H., Xia L., Zheng Y., Yu Y., Zhu Y., Chen G., Di W. NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells. Cancer Lett. 2009, 278:139-144.
8. Nakayama N., Nakayama K., Shamima Y., Ishikawa M., Katagiri A., Iida K., Miyazaki K. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 2010, 116:2621-2634.
9. Shahzad M.M., Lopez-Berestein G., Sood A.K. Novel strategies for reversing platinum resistance. Drug Resist Updat. 2009, 12:148-152.
10. Wei Shaoyin, Li Min Microtubule interfering agents: noscapine and its derivatives. Chin. J. New Drugs 2006, 15:1238-1243.
11. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 2002, 62:2478-2482.
12. Di Stefano V., Rinaldo C., Sacchi A., Soddu S., D'Orazi G. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp. Cell Res. 2004, 293:311-320.
13. Sakata K., Kwok T.T., Murphy B.J., Laderoute K.R., Gordon G.R., Sutherland R.M. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br. J. Cancer 1991, 64:809-814.
14. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13:139-168.
15. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 1999, 274:6519-6525.
16. Kikuchi Y., Kita T., Takano M., Kudoh K., Yamamoto K. Treatment options in the management of ovarian cancer. Expert Opin. Pharmacother. 2005, 6:743-754.
17. Aneja R., Vangapandu S.N., Lopus M., Chandra R., Panda D., Joshi H.C. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol. Pharmacol. 2006, 69:1801-1809.
18. Zhou J., Gupta K., Yao J., Ye K., Panda D., Giannakakou P., Joshi H.C. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J. Biol. Chem. 2002, 277:39777-39785.
19. Weng D., Song X., Xing H., Ma X., Xia X., Weng Y., Zhou J., Xu G., Meng L., Zhu T., Wang S., Ma D. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. Cancer Lett. 2009, 273:257-265.
20. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004, 64:1475-1482.
21. Seeber L.M., Zweemer R.P., Verheijen R.H., van Diest P.J. Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol. Int. 2010, 580971.
22. Tan C., de Noronha R.G., Roecker A.J., Pyrzynska B., Khwaja F., Zhang Z., Zhang H., Teng Q., Nicholson A.C., Giannakakou P., Zhou W., Olson J.J., Pereira M.M., Nicolaou K.C., Van Meir E.G. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005, 65:605-612.
23. Newcomb E.W., Lukyanov Y., Smirnova I., Schnee T., Zagzag D. Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway. Anticancer Drugs 2008, 19:553-563.
24. Newcomb E.W., Lukyanov Y., Schnee T., Ali M.A., Lan L., Zagzag D. Noscapine inhibits hypoxia-mediated HIF-1alpha expression and angiogenesis in vitro: a novel function for an old drug. Int. J. Oncol. 2006, 28:1121-1130.
25. Comerford K.M., Wallace T.J., Karhnausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62:3387-3394.
26. Tulpule A., Levine A.M., Berman N.E., Smith L., Auerbach A., Douer D. Phase I study of noscapine for patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia refractory to chemotherapy. Blood 2005, 106:3341.
27. Newcomb E.W., Lukyanov Y., Alonso-Basanta M., Esencay M., Smirnova I., Schnee T., Shao Y., Devitt M.L., Zagzag D., McBride W., Formenti S.C. Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71:1477-1484.
28. Sung B., Ahn K.S., Aggarwal B.B. Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-{kappa}B signaling pathway. Cancer Res. 2010, 70:3259-3268.
29. Altinoz M.A., Bilir A., Del Maestro R.F., Tuna S., Ozcan E., Gedikoglu G. Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol. 2006, 65:478-484.